Global Long-Acting Injectable (LAI) Antipsychotic Market Research Report 2023

Long-Acting Injectable (LAI) Antipsychotic Market

Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.

According to new survey, global Long-Acting Injectable (LAI) Antipsychotic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Long-Acting Injectable (LAI) Antipsychotic market research.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Long-Acting Injectable (LAI) Antipsychotic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Long-Acting Injectable (LAI) Antipsychotic Market Report

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Aripiprazole

1.2.3 Fluphenazine

1.2.4 Haloperidol

1.2.5 Others

1.3 Market by Application

1.3.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Perspective (2018-2029)

2.2 Long-Acting Injectable (LAI) Antipsychotic Growth Trends by Region

2.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Region (2018-2023)

2.2.3 Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Region (2024-2029)

2.3 Long-Acting Injectable (LAI) Antipsychotic Market Dynamics

2.3.1 Long-Acting Injectable (LAI) Antipsychotic Industry Trends

2.3.2 Long-Acting Injectable (LAI) Antipsychotic Market Drivers

2.3.3 Long-Acting Injectable (LAI) Antipsychotic Market Challenges

2.3.4 Long-Acting Injectable (LAI) Antipsychotic Market Restraints

3.1 Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Revenue

3.1.1 Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Revenue (2018-2023)

3.1.2 Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Players (2018-2023)

3.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Long-Acting Injectable (LAI) Antipsychotic Revenue

3.4 Global Long-Acting Injectable (LAI) Antipsychotic Market Concentration Ratio

3.4.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2022

3.5 Long-Acting Injectable (LAI) Antipsychotic Key Players Head office and Area Served

3.6 Key Players Long-Acting Injectable (LAI) Antipsychotic Product Solution and Service

3.7 Date of Enter into Long-Acting Injectable (LAI) Antipsychotic Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Type (2018-2023)

4.2 Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Type (2024-2029)

5.1 Global Long-Acting Injectable (LAI) Antipsychotic Historic Market Size by Application (2018-2023)

5.2 Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Application (2024-2029)

6.1 North America Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)

6.2 North America Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)

6.4 North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)

7.2 Europe Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)

7.4 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)

8.2 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023)

8.4 Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)

9.2 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)

9.4 Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size (2018-2029)

10.2 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)

10.4 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Alkermes

11.1.1 Alkermes Company Detail

11.1.2 Alkermes Business Overview

11.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Introduction

11.1.4 Alkermes Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.1.5 Alkermes Recent Development

11.2 Eli Lilly and Company

11.2.1 Eli Lilly and Company Company Detail

11.2.2 Eli Lilly and Company Business Overview

11.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Introduction

11.2.4 Eli Lilly and Company Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.2.5 Eli Lilly and Company Recent Development

11.3 Janssen Global Services, LLC

11.3.1 Janssen Global Services, LLC Company Detail

11.3.2 Janssen Global Services, LLC Business Overview

11.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Introduction

11.3.4 Janssen Global Services, LLC Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.3.5 Janssen Global Services, LLC Recent Development

11.4 Abilify Maintena

11.4.1 Abilify Maintena Company Detail

11.4.2 Abilify Maintena Business Overview

11.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Introduction

11.4.4 Abilify Maintena Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.4.5 Abilify Maintena Recent Development

11.5 Haldol

11.5.1 Haldol Company Detail

11.5.2 Haldol Business Overview

11.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Introduction

11.5.4 Haldol Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.5.5 Haldol Recent Development

11.6 Otsuka Pharmaceutical

11.6.1 Otsuka Pharmaceutical Company Detail

11.6.2 Otsuka Pharmaceutical Business Overview

11.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Introduction

11.6.4 Otsuka Pharmaceutical Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.6.5 Otsuka Pharmaceutical Recent Development

11.7 Aristada

11.7.1 Aristada Company Detail

11.7.2 Aristada Business Overview

11.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Introduction

11.7.4 Aristada Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.7.5 Aristada Recent Development

11.8 Prolixin

11.8.1 Prolixin Company Detail

11.8.2 Prolixin Business Overview

11.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Introduction

11.8.4 Prolixin Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.8.5 Prolixin Recent Development

11.9 Sumitomo Dainippon Pharma

11.9.1 Sumitomo Dainippon Pharma Company Detail

11.9.2 Sumitomo Dainippon Pharma Business Overview

11.9.3 Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Introduction

11.9.4 Sumitomo Dainippon Pharma Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

11.9.5 Sumitomo Dainippon Pharma Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Aripiprazole

    Table 3. Key Players of Fluphenazine

    Table 4. Key Players of Haloperidol

    Table 5. Key Players of Others

    Table 6. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023) & (US$ Million)

    Table 9. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Region (2018-2023)

    Table 10. Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 11. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Region (2024-2029)

    Table 12. Long-Acting Injectable (LAI) Antipsychotic Market Trends

    Table 13. Long-Acting Injectable (LAI) Antipsychotic Market Drivers

    Table 14. Long-Acting Injectable (LAI) Antipsychotic Market Challenges

    Table 15. Long-Acting Injectable (LAI) Antipsychotic Market Restraints

    Table 16. Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Players (2018-2023) & (US$ Million)

    Table 17. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Players (2018-2023)

    Table 18. Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Injectable (LAI) Antipsychotic as of 2022)

    Table 19. Ranking of Global Top Long-Acting Injectable (LAI) Antipsychotic Companies by Revenue (US$ Million) in 2022

    Table 20. Global 5 Largest Players Market Share by Long-Acting Injectable (LAI) Antipsychotic Revenue (CR5 and HHI) & (2018-2023)

    Table 21. Key Players Headquarters and Area Served

    Table 22. Key Players Long-Acting Injectable (LAI) Antipsychotic Product Solution and Service

    Table 23. Date of Enter into Long-Acting Injectable (LAI) Antipsychotic Market

    Table 24. Mergers & Acquisitions, Expansion Plans

    Table 25. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023) & (US$ Million)

    Table 26. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Type (2018-2023)

    Table 27. Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 28. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Type (2024-2029)

    Table 29. Global Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023) & (US$ Million)

    Table 30. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Application (2018-2023)

    Table 31. Global Long-Acting Injectable (LAI) Antipsychotic Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 32. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Application (2024-2029)

    Table 33. North America Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 34. North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)

    Table 35. North America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029) & (US$ Million)

    Table 36. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 37. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)

    Table 38. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029) & (US$ Million)

    Table 39. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 40. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023) & (US$ Million)

    Table 41. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2024-2029) & (US$ Million)

    Table 42. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 43. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 46. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023) & (US$ Million)

    Table 47. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2024-2029) & (US$ Million)

    Table 48. Alkermes Company Detail

    Table 49. Alkermes Business Overview

    Table 50. Alkermes Long-Acting Injectable (LAI) Antipsychotic Product

    Table 51. Alkermes Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 52. Alkermes Recent Development

    Table 53. Eli Lilly and Company Company Detail

    Table 54. Eli Lilly and Company Business Overview

    Table 55. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Product

    Table 56. Eli Lilly and Company Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 57. Eli Lilly and Company Recent Development

    Table 58. Janssen Global Services, LLC Company Detail

    Table 59. Janssen Global Services, LLC Business Overview

    Table 60. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Product

    Table 61. Janssen Global Services, LLC Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 62. Janssen Global Services, LLC Recent Development

    Table 63. Abilify Maintena Company Detail

    Table 64. Abilify Maintena Business Overview

    Table 65. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Product

    Table 66. Abilify Maintena Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 67. Abilify Maintena Recent Development

    Table 68. Haldol Company Detail

    Table 69. Haldol Business Overview

    Table 70. Haldol Long-Acting Injectable (LAI) Antipsychotic Product

    Table 71. Haldol Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 72. Haldol Recent Development

    Table 73. Otsuka Pharmaceutical Company Detail

    Table 74. Otsuka Pharmaceutical Business Overview

    Table 75. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Product

    Table 76. Otsuka Pharmaceutical Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 77. Otsuka Pharmaceutical Recent Development

    Table 78. Aristada Company Detail

    Table 79. Aristada Business Overview

    Table 80. Aristada Long-Acting Injectable (LAI) Antipsychotic Product

    Table 81. Aristada Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 82. Aristada Recent Development

    Table 83. Prolixin Company Detail

    Table 84. Prolixin Business Overview

    Table 85. Prolixin Long-Acting Injectable (LAI) Antipsychotic Product

    Table 86. Prolixin Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 87. Prolixin Recent Development

    Table 88. Sumitomo Dainippon Pharma Company Detail

    Table 89. Sumitomo Dainippon Pharma Business Overview

    Table 90. Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Product

    Table 91. Sumitomo Dainippon Pharma Revenue in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023) & (US$ Million)

    Table 92. Sumitomo Dainippon Pharma Recent Development

    Table 93. Research Programs/Design for This Report

    Table 94. Key Data Information from Secondary Sources

    Table 95. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Type: 2022 VS 2029

    Figure 3. Aripiprazole Features

    Figure 4. Fluphenazine Features

    Figure 5. Haloperidol Features

    Figure 6. Others Features

    Figure 7. Global Long-Acting Injectable (LAI) Antipsychotic Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 8. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Application: 2022 VS 2029

    Figure 9. Hospital Case Studies

    Figure 10. Retail Pharmacy Case Studies

    Figure 11. Others Case Studies

    Figure 12. Long-Acting Injectable (LAI) Antipsychotic Report Years Considered

    Figure 13. Global Long-Acting Injectable (LAI) Antipsychotic Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 14. Global Long-Acting Injectable (LAI) Antipsychotic Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 15. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Region: 2022 VS 2029

    Figure 16. Global Long-Acting Injectable (LAI) Antipsychotic Market Share by Players in 2022

    Figure 17. Global Top Long-Acting Injectable (LAI) Antipsychotic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Injectable (LAI) Antipsychotic as of 2022)

    Figure 18. The Top 10 and 5 Players Market Share by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2022

    Figure 19. North America Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. North America Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2029)

    Figure 21. United States Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Canada Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2029)

    Figure 25. Germany Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. France Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. U.K. Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Italy Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Russia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Nordic Countries Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Long-Acting Injectable (LAI) Antipsychotic Market Share by Region (2018-2029)

    Figure 33. China Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Japan Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. South Korea Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. India Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Australia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2029)

    Figure 41. Mexico Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Brazil Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Share by Country (2018-2029)

    Figure 45. Turkey Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Saudi Arabia Long-Acting Injectable (LAI) Antipsychotic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Alkermes Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 48. Eli Lilly and Company Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 49. Janssen Global Services, LLC Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 50. Abilify Maintena Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 51. Haldol Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 52. Otsuka Pharmaceutical Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 53. Aristada Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 54. Prolixin Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 55. Sumitomo Dainippon Pharma Revenue Growth Rate in Long-Acting Injectable (LAI) Antipsychotic Business (2018-2023)

    Figure 56. Bottom-up and Top-down Approaches for This Report

    Figure 57. Data Triangulation

    Figure 58. Key Executives Interviewed